Stephen H. Willard
Biography
 |
Executive and Financial Management, Corporate and Government Oversight, Law B.A., Williams College, 1982 J.D., Yale Law School, 1985 |
Steve Willard is the Chief Executive Officer of NRx Pharmaceuticals. He has been the chief executive officer of both private and public companies in the bio/pharmaceutical sector. He has practiced law in New York, London and Washington D.C. and was an investment banker for a time.
From 2012 to 2021, Willard served as chief executive officer of Cellphire Therapeutics. He built the company from 5 to 55 people, completed two successful clinical trials and initiated a third one, and increased the stock price 2000%. The company has a revolutionary method of storing human platelets for years, rather than the current 5-7 days.
From 2005 to 2012, Willard served as CEO and then Chairman of Flamel Technologies, S.A., a NASDAQ – traded international pharmaceutical controlled release technology company. He has developed, executed and managed multinational partnerships and corporate transactions worldwide.
Willard was a member of the Board of Directors of ETRADE Financial and/or its bank from 2000-2014, where he had stints as Chairman of the Bank Audit Committee, Head of Risk Oversight Committee, and Vice-Chairman. Willard is highly experienced with boards of directors on both the management, and outside board member, roles.
Willard has a unique background in financial institutions, having served as Associate Director of Resolutions for the Federal Deposit Insurance Corporation (FDIC), an SES-2 level position, from 1991-1994. He managed the resolution of the nation’s largest troubled banks during this period. His decisions were favorably reviewed in multiple Government Accountability Office (GAO) audits.
Willard is a member of the National Science Board’s class of 2018-2024.